Developing novel chemistries for removing environmental surface biofilms to reduce hospital acquired infections. This project will develop new detergents that more efficiently clean hospitals. This will increase hospital safety by decreasing infections, thus saving lives and healthcare costs.
Emergence of a virulent strain of West Nile virus causing fatal equine encephalitis in south-eastern Australia. In 2011 a large outbreak of encephalitis in horses occurred in south-eastern Australia that was caused by a new virus that is transmitted by mosquitoes and is related to West Nile virus, known to cause severe disease in humans and horses. This project will study this new virus and develop improved methods for diagnosis and control of this disease.
Identification of new antibacterial agents that inhibit type III secretion. The development of new antibacterial drugs is an unmet global health priority. This project will investigate several plant-derived compounds that have been found to display promising antibacterial activity. This project has the potential to identify compounds that may result in a new antibiotic therapy.
A single vaccine for influenza and pneumonia. Influenza and bacterial pneumonia collaborate to kill millions of people each year. This project aims to develop a single vaccine that will provide long-lasting protection against both influenza and pneumonia.
The development and evaluation of a new therapy for the prevention and treatment of bacterial infections in hospitals. The technology used in this project will enable products to be developed from the Australian dairy industry which may safely provide protection and treatment for diarrhoea acquired in hospitals for which there are few effective options. The product will be cost effective and can be used as a public health tool to control outbreaks in those most susceptible to severe disease.
Structure-based design of inhibitors of HIV-1 integrase. This project will produce compounds that block human immunodeficiency virus (HIV) replication. These compounds will benefit the 17000 Australians and more than 34 million people worldwide who are currently suffering with this terrible disease.
Novel antimicrobial surface coatings for biomedical applications. There are currently no effective biomaterial coatings to reduce device related infections. Such materials are needed to address the high rates of infection that can occur. The melimine technology proposed here has the potential to significantly reduce rates of infection, reduce health care costs and advantage the Australian biomaterials industry.
Rational design of new drug candidates for the treatment of Trypanosoma cruzi infection. There is a serious shortage of safe and effective drugs to treat Chagas disease which is caused by a parasitic infection. This project aims to design and identify new drug candidates by defining the disposition profile within the body which is necessary to achieve a therapeutic effect.
Rapid Pathogen Detection using Super-Sensitive Multiplexing Nanophotonic Probes. Responding to an urgent need to advance rapid molecular diagnostics, this project aims to explore new photonics and biochemistry approaches to DNA recognition. It is anchored on proprietary light-emitting nanodots which have single-molecule sensitivity in conjunction with tunable optical identities. The project aims to develop a multiplexing reagent library of DNA probes to sense trace DNA molecules and to recognise ....Rapid Pathogen Detection using Super-Sensitive Multiplexing Nanophotonic Probes. Responding to an urgent need to advance rapid molecular diagnostics, this project aims to explore new photonics and biochemistry approaches to DNA recognition. It is anchored on proprietary light-emitting nanodots which have single-molecule sensitivity in conjunction with tunable optical identities. The project aims to develop a multiplexing reagent library of DNA probes to sense trace DNA molecules and to recognise multiple pathogens in a single assay. This innovation aims to create a hybrid-Polymerase Chain Reaction (PCR) technology platform for current industry-standard pathogen detection tests. The outcomes of the project aim to enable DNA based pathogen diagnostics within 90 minutes, four times faster than the current tests.Read moreRead less
Fragment based screening to deliver drugs targeting tuberculosis and the gametocyte and liver stages of Plasmodium. This project will identify natural products that bind to critical proteins in malaria and tuberculosis to discover new ways to treat these diseases.